[go: up one dir, main page]

TW200501956A - Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine - Google Patents

Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine

Info

Publication number
TW200501956A
TW200501956A TW093108719A TW93108719A TW200501956A TW 200501956 A TW200501956 A TW 200501956A TW 093108719 A TW093108719 A TW 093108719A TW 93108719 A TW93108719 A TW 93108719A TW 200501956 A TW200501956 A TW 200501956A
Authority
TW
Taiwan
Prior art keywords
migraine
oxoquinazolin
tyrosyl
sumatriptan
lysyl
Prior art date
Application number
TW093108719A
Other languages
English (en)
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200501956A publication Critical patent/TW200501956A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW093108719A 2003-04-01 2004-03-30 Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine TW200501956A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10314617A DE10314617A1 (de) 2003-04-01 2003-04-01 Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne

Publications (1)

Publication Number Publication Date
TW200501956A true TW200501956A (en) 2005-01-16

Family

ID=32980861

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093108719A TW200501956A (en) 2003-04-01 2004-03-30 Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine

Country Status (9)

Country Link
EP (1) EP1631282A1 (zh)
JP (1) JP2006522044A (zh)
AR (1) AR043793A1 (zh)
CA (1) CA2520930A1 (zh)
CL (1) CL2004000686A1 (zh)
DE (1) DE10314617A1 (zh)
TW (1) TW200501956A (zh)
UY (1) UY28251A1 (zh)
WO (1) WO2004087134A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563687A1 (en) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
WO2010046399A1 (en) * 2008-10-22 2010-04-29 Novartis Ag Combinations for the treatment of migraine
US9918932B2 (en) 2016-02-19 2018-03-20 Zosano Pharma Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096

Also Published As

Publication number Publication date
DE10314617A1 (de) 2004-10-14
UY28251A1 (es) 2004-11-08
AR043793A1 (es) 2005-08-10
CA2520930A1 (en) 2004-10-14
JP2006522044A (ja) 2006-09-28
EP1631282A1 (de) 2006-03-08
CL2004000686A1 (es) 2005-02-04
WO2004087134A1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2002048183A3 (en) Compositions of peptide crystals
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
IL145429A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
CA2433585A1 (en) Pharmaceutical compositions containing donepezil hydrochloride
UA90518C2 (ru) Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
SE0102440D0 (sv) New compound
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
TW200501956A (en) Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine
MXPA06003122A (es) Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
TW200633694A (en) Composition and method for treating asthma
SE0002729D0 (sv) Novel compound form
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
TW200638927A (en) Bambuterol and integrin inhibitor combination
WO2002055022A3 (en) Active metabolite of antifungal compound
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
WO2001079195A3 (en) Pyridine and pyrazine derivatives as thrombin inhibitors
ECSP045241A (es) Producto de inhala­ción en polvo que contiene el antagonista de CGRP, BIBN4096, y procedimiento para su preparación
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine